Drugs Made In America Acquisition Corp (DMAA) Price Prediction & ForecastDMAADrugs Made In America Acquisition Corp

Alphio's DMAA stock price prediction model matches the current Drugs Made In America Acquisition Corp tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $10.85 (-0.32%). The 1-week path is $11.02 (+1.28%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Currently, DMAA is trading at $10.89, which is 97.5% of its 52-week high of $10.90. The RSI is at 59.42, indicating the asset is nearing overbought territory, which suggests caution. While the stock has shown a year-to-date change of +4.87%, the forward P/E is 0, indicating a lack of earnings growth expectations. The main risk is the current ratio of 0.02, suggesting potential liquidity issues.

Drugs Made In America Acquisition Corp (DMAA) last closed at $10.8800001, gaining +0.00%. These facts feed the 1-day and 1-week DMAA price prediction above.